Capstone Capital Management Ltd Buys Shares of 19,562 Legend Biotech Corporation Sponsored ADR $LEGN

Posted by Brenda Bartman on May 19th, 2026

Capstone Capital Management Ltd bought a new position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 19,562 shares of the company’s stock, valued at approximately $425,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Clearstead Advisors LLC grew its holdings in shares of Legend Biotech by 76.5% during the 3rd quarter. Clearstead Advisors LLC now owns 847 shares of the company’s stock valued at $28,000 after purchasing an additional 367 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of Legend Biotech by 171.9% during the third quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock valued at $34,000 after buying an additional 662 shares during the period. Raymond James Financial Inc. bought a new position in Legend Biotech in the 2nd quarter worth $78,000. Harvest Fund Management Co. Ltd bought a new position in Legend Biotech in the third quarter worth about $104,000. Finally, Public Employees Retirement System of Ohio raised its position in shares of Legend Biotech by 31.0% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 3,800 shares of the company’s stock worth $124,000 after acquiring an additional 900 shares in the last quarter. Hedge funds and other institutional investors own 70.89% of the company’s stock.

Legend Biotech Stock Performance

Shares of NASDAQ LEGN opened at $26.98 on Tuesday. The company has a market cap of $4.99 billion, a P/E ratio of -39.68 and a beta of 0.29. Legend Biotech Corporation Sponsored ADR has a 52-week low of $16.24 and a 52-week high of $45.30. The firm’s fifty day moving average is $21.47 and its two-hundred day moving average is $22.58.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The business had revenue of $305.10 million for the quarter, compared to the consensus estimate of $306.51 million. Legend Biotech had a negative net margin of 21.98% and a negative return on equity of 24.92%. Legend Biotech’s revenue for the quarter was up 56.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.07) EPS. As a group, analysts forecast that Legend Biotech Corporation Sponsored ADR will post 0.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LEGN. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Legend Biotech in a research note on Monday. Jefferies Financial Group reaffirmed a “buy” rating and set a $69.00 price target on shares of Legend Biotech in a report on Tuesday, March 10th. Royal Bank Of Canada raised their target price on shares of Legend Biotech from $62.00 to $64.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. Rothschild & Co Redburn downgraded Legend Biotech from a “buy” rating to a “neutral” rating and set a $24.00 price target for the company. in a research note on Thursday, February 12th. Finally, Weiss Ratings downgraded shares of Legend Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Eleven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $59.00.

Read Our Latest Report on Legend Biotech

Insiders Place Their Bets

In related news, CEO Ying Huang sold 9,936 shares of Legend Biotech stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $8.77, for a total transaction of $87,138.72. Following the completion of the sale, the chief executive officer owned 247,438 shares in the company, valued at $2,170,031.26. This trade represents a 3.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.02% of the stock is owned by insiders.

Legend Biotech Company Profile

(Free Report)

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.